As of June 30, 2026, BioXcel Therapeutics, Inc. carries a market capitalization of 44.14M, placing it among publicly traded companies globally. Its enterprise value stands at 135.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 44.14M |
| Enterprise Value | 135.75M |
BioXcel Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.
| Earnings Date | 11/18/2026 |
As of June 30, 2026, BioXcel Therapeutics, Inc. has 31.31M shares outstanding.
| Shares Outstanding | 31.31M |
These figures are as of June 30, 2026. The price-to-sales ratio is 38.14, and the price-to-book ratio stands at -0.38.
| PS Ratio | 38.14 |
| PB Ratio | -0.38 |
| P/TBV Ratio | -0.38 |
| P/FCF Ratio | -0.56 |
| P/OCF Ratio | -0.56 |
These figures are as of June 30, 2026. The EV/Sales ratio of 182.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 135.75M versus a market cap of 44.14M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 182.95 |
As of June 30, 2026, BioXcel Therapeutics, Inc. maintains a current ratio of 0.21, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -90.47, indicating conservative leverage, while an interest coverage ratio of -2.60 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.21 |
| Quick Ratio | 0.09 |
| Debt / Equity | -90.47 |
| Debt / EBITDA | -2.34 |
| Interest Coverage | -2.60 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -259.62, reflecting losses generated across the asset base. The company generates approximately 23,935.48 in revenue per employee across its workforce of 31.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.70 indicates how many times BioXcel Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -259.62 |
| Revenue Per Employee | 23,935.48 |
| Employee Count | 31.00 |
| Inventory Turnover | 0.70 |
As of the close on November 16, 2026, BioXcel Therapeutics, Inc.'s stock has declined approximately 99.33% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.89.
| 52-Week Price Change | -99.33% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.89 |
Over the twelve months ended June 30, 2026, BioXcel Therapeutics, Inc. generated 742,000.00 in revenue and converted that into -70.86M in net income, yielding earnings per share of -3.53. EBITDA reached -44.70M, while operating income came in at -44.73M.
| Revenue | 742,000.00 |
| Gross Profit | 394,000.00 |
| Operating Income | -44.73M |
| Pretax Income | -70.86M |
| Net Income | -70.86M |
| EBITDA | -44.70M |
| EBIT | -44.93M |
| Earnings Per Share (EPS) | -3.53 |
As of June 30, 2026, BioXcel Therapeutics, Inc. holds 12.84M in cash and equivalents against 104.45M in total debt, resulting in a net debt position of 91.61M. Total book value stands at -115.46M, with working capital of -108.45M providing operational flexibility.
| Cash & Cash Equivalents | 12.84M |
| Total Debt | 104.45M |
| Net Debt | 91.61M |
| Equity (Book Value) | -115.46M |
| Book Value Per Share | -3.69 |
| Working Capital | -108.45M |
BioXcel Therapeutics, Inc. produced -50.90M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -50.90M - equivalent to -2.54 per share.
| Operating Cash Flow | -50.90M |
| Free Cash Flow | -50.90M |
| FCF Per Share | -2.54 |
Over the twelve months ended June 30, 2026, BioXcel Therapeutics, Inc. posted a gross margin of 53.10, reflecting its pricing power and cost economics. The operating margin of -6,028.57 and net profit margin of -9,549.87 provide insight into operational efficiency.
| Gross Margin | 53.10 |
| Operating Margin | -6,028.57 |
| Pretax Margin | -9,549.87 |
| Profit Margin | -9,549.87 |
| EBITDA Margin | -6,024.39 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -179.89: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -104.51, meaning BioXcel Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -104.51 |
| FCF Yield | -179.89 |
BioXcel Therapeutics, Inc.'s most recent stock split took place on February 10, 2025 with a 16:1 split ratio.
| Last Split Date | 2/10/2025 |
| Split Ratio | 16:1 |
As of June 30, 2026, BioXcel Therapeutics, Inc. has an Altman Z-Score of -45.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -45.77 |